“Shadow Lord” picks up one year after the Clone Wars, following the activation of Order 66 and the Empire’s occupation across the galaxy. The story takes place on Janix, a gray-paletted, ...

Patients with age-related macular degeneration (AMD) initially may present with distortions in fine visual perception, and disease may be asymptomatic. As the disease develops over time, vision ...

AlgorithmicTypography is a Processing library that enables designers, researchers, and artists to explore parametric typography systems. It generates animated grids of typographic characters whose ...

Creating a space that feels truly good to live in isn’t about following trends or filling rooms with expensive pieces. The most successful interiors balance three essentials: comfort, function, and ...

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...

Complement-mediated hemolytic uremic syndrome (CM-HUS), commonly referred to as atypical HUS, is a rare thrombotic microangiopathy caused by uncontrolled activation of the alternative complement ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...

It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...